[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481838":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":84,"collaborators":87,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":10,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":10,"enrollmentInfo":106,"targetDuration":109,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Institut Investigacio Sanitaria Pere Virgili","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Severe obesity without liver disease",null,"Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 0-2).",[13],"Diagnostic Test: To propose diagnostic tests for liver diseases before surgical decisions.",{"label":15,"type":10,"description":16,"interventionNames":17},"Severe obesity with liver disease without criteria for steatohepatitis","Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis, but their biopsies presented some liver severity (scores 3 and 4).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Severe obesity with well-defined steatohepatitis and\u002For cirrhosis","Patients with severe obesity who met the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 5-8).",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DIAGNOSTIC_TEST","To propose diagnostic tests for liver diseases before surgical decisions.","Observational although patients are candidates for metabolic surgery.",[15,19,9],[29],"External follow up monitoring liver diseases and weight loss.",[31],{"name":32,"affiliation":5,"role":33},"Jorge Joven, Professor","PRINCIPAL_INVESTIGATOR",[35,40],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","+34977310300","55409","jorge.joven@urv.cat",{"name":41,"role":36,"phone":37,"phoneExt":38,"email":42},"Helena Castañé, MSc","helena.castane@iispv.cat",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hospital Universitari Sant Joan","RECRUITING","Reus","Tarragona","43204","Spain","ES",{"type":53,"coordinates":54},"Point",[55,56],1.10687,41.15612,{"lat":56,"lon":55},[59,60,61,63,65,67,69,71,73,75,77,79,80,82],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},{"name":32,"role":36,"phone":10,"phoneExt":10,"email":10},{"name":62,"role":36,"phone":10,"phoneExt":10,"email":10},"Daniel del Castillo, Professor",{"name":64,"role":36,"phone":10,"phoneExt":10,"email":10},"Jordi Camps, PhD",{"name":66,"role":36,"phone":10,"phoneExt":10,"email":10},"Isabel Fort-Gallifa, PhD",{"name":68,"role":36,"phone":10,"phoneExt":10,"email":10},"Anna Hernández-Aguilera, PhD",{"name":70,"role":36,"phone":10,"phoneExt":10,"email":10},"Marta Paris, PhD",{"name":72,"role":36,"phone":10,"phoneExt":10,"email":10},"Gerard Baiges-Gaya, MSc",{"name":74,"role":36,"phone":10,"phoneExt":10,"email":10},"Elisabet Rodríguez-Tomàs, MSc",{"name":76,"role":36,"phone":10,"phoneExt":10,"email":10},"Jordi Riu, PhD",{"name":78,"role":36,"phone":10,"phoneExt":10,"email":10},"Adria Cereto-Massague, PhD",{"name":41,"role":36,"phone":10,"phoneExt":10,"email":10},{"name":81,"role":36,"phone":10,"phoneExt":10,"email":10},"Andrea Jiménez-Franco, MSc",{"name":83,"role":36,"phone":10,"phoneExt":10,"email":10},"Alina-Iuliana Onoiu, MSc",{"type":33,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jorge Joven","Professor of Medicine at the Rovira i Virgili University",[88,90,92,95],{"name":45,"class":89},"UNKNOWN",{"name":91,"class":6},"La Caixa Foundation",{"name":93,"class":94},"Instituto de Salud Carlos III","OTHER_GOV",{"name":96,"class":6},"University of Barcelona","100481838","integrated-multi-omics-data-for-personalized-treatment-of-obesity-associated-fatty-liver-disease-100481838",false,"NCT05554224","Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease","Integrated Multi-omics and Machine Learning-driven Personalized Treatment of Obesity-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Body mass index greater or equal to 40 kg\u002Fm\\^2.\n* Body mass index between 35 and 40 kg\u002Fm\\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).\n* Positive psychiatric evaluation.\n* Age greater or equal to 18 years old.\n\nExclusion Criteria:\n\n* Legal or illegal drug consumption, including alcohol.\n* Diagnosis of Hepatitis.\n* Current cancer diagnosis or treatment.\n* Clinical or analytical evidence of severe illness.\n* Clinical or analytical evidence of chronic or acute inflammation.\n* Clinical or analytical evidence of infectious diseases.\n* Clinical or analytical evidence of terminal illness.","ALL","18 Years",{"count":107,"type":108},1104,"ESTIMATED","10 Years","OBSERVATIONAL","The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.",[113,114,115],"NAFLD","Obesity, Morbid","Comorbidities and Coexisting Conditions",[117,118,119,120,121,122,123,124],"Weight loss","Bariatric surgery","Liver diseases","Mass spectrometry","Proteomics","Lipidomics","Metabolomics","Transcriptomics","2024-11-11",{"date":127,"type":128},"2024-11-13","ACTUAL",{"date":130,"type":128},"2008-06-25",{"date":132,"type":108},"2028-12-31",{"name":5,"class":6},1]